Navigation Links
Advanced Life Sciences to Host Conference Call to Discuss Data From,Cethromycin's First of Two Phase 3 Pneumonia Trials

CHICAGO, June 29, 2007 /PRNewswire-FirstCall/ -- Advanced Life Sciences Holdings, Inc. , today announced that it will host a conference call and live webcast at 10:00 am (EDT) on Monday, July 2, 2007 to discuss data from Trial CL-06, the first of two pivotal Phase 3 clinical trials designed to assess the safety and effectiveness of cethromycin, a novel once-a-day antibiotic, for the treatment of community acquired pneumonia (CAP).

Conference Call Details:

The conference call will be webcast simultaneously over the Internet. Please visit the Investor Relations section of the Advanced Life Sciences corporate website http://www.advancedlifesciences.com. Alternatively, callers may participate in the conference call by dialing 800-561-2601(domestic) or 617-614-3518 (international). The passcode for the conference call is 84510433. A replay of the conference call will be available until August 2, 2007. Callers may access the telephone replay by dialing 888-286-8010 (domestic) or 617-801-6888 (international), passcode 90055877.

About Advanced Life Sciences

Advanced Life Sciences is a biopharmaceutical company engaged in the discovery, development and commercialization of novel drugs in the therapeutic areas of infection, cancer and inflammation. The Company's lead candidate, cethromycin, is a novel once-a-day antibiotic in late-stage clinical development for the treatment of respiratory tract infections including CAP. For more information, please visit us on the web at http://www.advancedlifesciences.com.

Forward-Looking Statements

Any statements contained in this press release that relate to future plans, events or performance are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forw ard-looking statements are subject to a number of risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. These risks and uncertainties include, among others, those relating to technology and product development, clinical trials, market acceptance, government regulation and regulatory approval processes, intellectual property rights and litigation, dependence on collaborative relationships, ability to obtain financing, competitive products, industry trends and other risks identified in Advanced Life Sciences' filings with the Securities and Exchange Commission. Advanced Life Sciences undertakes no obligation to update or alter these forward-looking statements as a result of new information, future events or otherwise.

CONTACT: Joe Camp of Advanced Life Sciences Holdings, Inc.,+1-630-754-4352

Web site: http://www.advancedlifesciences.com/

Ticker Symbol: (NASDAQ-NMS:ADLS)

Terms and conditions of use apply
Copyright © 2007 PR Newswire Association LLC. All rights reserved.
A United Business Media Company


'"/>




Related medicine technology :

1. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
2. BusinessWeek Article Highlights Promising Breakthrough Treatment for Advanced Coronary Artery Disease
3. BusinessWeek Article Highlights Promising Breakthrough Treatment for Advanced Coronary Artery Disease
4. Advanced Life Sciences Announces Supplemental Efficacy Data from First Pivotal Phase 3 Pneumonia Clinical Trial
5. Progenics and Wyeth Announce Positive Results from Three-Month Clinical-Extension Study of Subcutaneous Methylnaltrexone for the Treatment of Opioid-Induced Constipation in Patients with Advanced Illness
6. Advanced Cell Technology Develops First Human Embryonic Stem Cell Line without Destroying an Embryo
7. Neurologix Announces Publication of Landmark Gene Therapy Study Demonstrating Safety and Statistically Significant Improvement in Patients With Advanced Parkinsons Disease
8. Advanced Viral Research Corp. Announces Positive Preliminary Findings from Ongoing Phase II Dermatological Study
9. Clinical Data Reported on Vidaza in Hematologic Malignancies and Advanced Solid Tumors
10. Updated Study Results Reinforce Survival Benefit of Taxotere (Docetaxel) for Men with Advanced, Hormone-Resistant Prostate Cancer
11. GSKS Pazopanib Shows Positive Results in Patients with Advanced Renal Cell Carcinoma, Ovarian Cancer and Soft Tissue Sarcoma
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/24/2017)... IBM (NYSE: IBM ) has been recognized as a ... for the fourth year in a row. 1 ... the Leaders quadrant have the highest scores for their Ability ... Leaders quadrant has the market share, credibility, and marketing and ... These vendors demonstrate a clear understanding of market needs; they ...
(Date:7/21/2017)... and RESEARCH TRIANGLE PARK, N.C. ... Corporation (NASDAQ: UTHR ) announced today that ... before the market opens on Thursday, July 27, 2017. ... host a teleconference on Thursday, July 27, 2017, at ... dialing 1-877-351-5881, with international callers dialing 1-970-315-0533.  A rebroadcast ...
(Date:7/20/2017)... , July 20, 2017  Prime Therapeutics LLC (Prime) released ... , M.D., following today,s Institute for Clinical and Economic Review,s ... on the effectiveness and value of abuse-deterrent formulations (ADF) of ... policy roundtable at the meeting. ... material cost benefit to the use of abuse-deterrent formulations (ADF) ...
Breaking Medicine Technology:
(Date:7/26/2017)... ... July 26, 2017 , ... “We are thrilled to be partnering with ... to schedule an appointment online in real time,” said Keith English, LocalMed CEO. “Allowing ... directory will bring more Six Month Smiles patients to their providers.” , Each month, ...
(Date:7/26/2017)... ... July 26, 2017 , ... Isodiol ... global cannabis innovator, specializing in the development of pharmaceutical and consumer products, announces ... 2017 to June 30, 2017. Iso International LLC recorded unaudited fiscal Q1 profits ...
(Date:7/26/2017)... ... 26, 2017 , ... BioPlus Specialty Pharmacy (BioPlus), ... of the HCV Treatment Path app (version 4.4.0) to keep health care providers ... All of the latest HCV medications are included in this app, including Vosevi™ ...
(Date:7/25/2017)... , ... July 25, 2017 , ... Summers in Palm ... the air conditioner — think homemade gourmet ice cream, sparkling pools, and mile-high fun. ... shop featuring fun mugs, journals, and other must-have knick knacks. Ice cream and sorbet ...
(Date:7/25/2017)... ... July 25, 2017 , ... SureVest Insurance ... services to communities across North Carolina, is launching a charity event in conjunction ... support for the ongoing fight against bladder cancer. , The Bladder Cancer Advocacy ...
Breaking Medicine News(10 mins):